ACTICLATE CAP Drug Patent Profile

« Back to Dashboard

Which patents cover Acticlate Cap, and when can generic versions of Acticlate Cap launch?

Acticlate Cap is a drug marketed by Chartwell Rx and is included in one NDA.

The generic ingredient in ACTICLATE CAP is doxycycline hyclate. There is one drug master file entry for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Acticlate Cap

A generic version of ACTICLATE CAP was approved as doxycycline hyclate by STRIDES PHARMA on March 29^th, 1982.

Summary for ACTICLATE CAP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	52
Patent Applications:	2,651
DailyMed Link:	ACTICLATE CAP at DailyMed

Pharmacology for ACTICLATE CAP

Drug Class

Tetracycline-class Drug

US Patents and Regulatory Information for ACTICLATE CAP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	ACTICLATE CAP	doxycycline hyclate	CAPSULE;ORAL	208253-001	Apr 26, 2016		DISCN	Yes	No

Acticlate CAP Market Dynamics and Financial Trajectory

Last updated: October 3, 2026

Acticlate CAP is a branded doxycycline hyclate capsule sold in the U.S. for bacterial infections and selected inflammatory dermatologic conditions. Its commercial position is constrained by an old active ingredient, extensive generic competition, limited differentiation from other doxycycline products, and the absence of publicly reported brand-level revenue. The product’s financial trajectory is therefore more dependent on pricing, channel access, prescribing persistence, and portfolio strategy than on patent exclusivity.

What is Acticlate CAP and who markets it?

Acticlate CAP is an oral capsule formulation of doxycycline hyclate. The product is associated with Avion Pharmaceuticals, a specialty pharmaceutical company focused on branded and generic prescription products, including dermatology products.

Attribute	Acticlate CAP
Active ingredient	Doxycycline hyclate
Dosage form	Oral capsule
Common strengths	75 mg and 150 mg listings have been associated with the product
Therapeutic category	Tetracycline antibiotic
Major use areas	Bacterial infections, acne, rosacea and other inflammatory dermatologic conditions
U.S. regulatory pathway	Abbreviated New Drug Application or New Drug Application product framework, depending on the specific presentation
Brand owner or marketer	Avion Pharmaceuticals-associated product portfolio
Patent profile	No meaningful composition-of-matter exclusivity remains
Primary commercial risk	Generic substitution and reimbursement pressure

The product should be distinguished from Acticlate tablets and from generic doxycycline hyclate capsules. FDA labeling for doxycycline products includes multiple dosage forms, strengths and indications, but therapeutic interchangeability depends on the specific product, dosage form and prescription instructions.[1]

What is the FDA regulatory status of Acticlate CAP?

Acticlate CAP is an FDA-regulated prescription doxycycline product. Doxycycline hyclate capsules are established products with long clinical and regulatory histories. The FDA Orange Book lists approved doxycycline products across multiple manufacturers and dosage forms.[2]

The principal regulatory characteristics are:

• The active ingredient is well established.
• The product does not rely on a novel molecular mechanism.
• FDA approval risk is lower than for a new chemical entity.
• Manufacturing, bioequivalence, stability and quality-control compliance remain material.
• The product competes against approved generic doxycycline products.

The FDA label for doxycycline hyclate identifies contraindications, warnings related to tooth discoloration and skeletal effects, photosensitivity, gastrointestinal reactions, intracranial hypertension and antibacterial resistance.[1] These risks apply broadly to doxycycline products and do not create a strong brand-specific barrier.

What is the Orange Book status of Acticlate CAP?

The Orange Book is the principal source for determining therapeutic-equivalence codes, approved applications and listed patent information for FDA-approved drug products.[2] For an established doxycycline capsule, the relevant commercial issue is generally whether an approved generic carries an AB therapeutic-equivalence rating for the same reference product and dosage form.

Acticlate’s commercial protection is not based on a new active ingredient. Any remaining listed patents, if applicable to a specific presentation, would be formulation, method-of-use or other secondary patents rather than core molecule patents. Publicly available FDA and patent records do not indicate a durable, high-value patent barrier comparable to the protection surrounding a recently approved branded drug.

What patents protect Acticlate CAP?

Acticlate CAP does not have meaningful remaining composition-of-matter protection because doxycycline has been marketed for decades. The relevant patent categories are:

Patent category	Commercial relevance
Doxycycline molecule patents	Expired
Doxycycline hyclate salt protection	Expired or commercially exhausted
Capsule formulation patents	Potentially relevant only if specifically listed and enforceable
Method-of-use patents	Potentially relevant for narrow indications
Manufacturing patents	May protect processes but rarely prevent generic launch by themselves
Device or delivery patents	Not central to the capsule product

A brand may still pursue secondary intellectual-property rights involving dosage, release profile, excipients, packaging or specific treatment methods. These rights generally have narrower claim scope than a new chemical entity patent and are more vulnerable to design-around strategies.

What formulations are protected by Acticlate-related patents?

The commercial distinction among Acticlate products is primarily dosage form and strength rather than a clearly differentiated delivery technology. A conventional immediate-release doxycycline capsule has limited formulation-based defensibility unless it incorporates a technically distinct release system, reduced-irritation platform or other measurable performance advantage.

A generic manufacturer can potentially avoid a formulation claim by changing excipients, capsule composition, manufacturing parameters or release characteristics while maintaining bioequivalence. That limits the practical value of secondary formulation patents.

When does Acticlate CAP lose exclusivity?

Acticlate CAP effectively lacks the type of exclusivity that supports a protected launch window for a modern branded drug. Doxycycline’s underlying exclusivity expired long before Acticlate entered the market.

Exclusivity type	Acticlate CAP position
New chemical entity exclusivity	Not available
Five-year NCE exclusivity	Not applicable
Three-year new clinical investigation exclusivity	No broad protection identified
Orphan-drug exclusivity	Not applicable to the general product
Pediatric exclusivity	No material product-specific barrier identified
Core composition patent	Expired
Secondary formulation or method patents	Limited potential, if any
Generic competition	Established

This means the product’s practical exclusivity depends on branding, prescriber familiarity, distribution, reimbursement and any commercial contracting rather than statutory market protection.

How many patents cover Acticlate CAP?

There is no clear public basis for treating Acticlate CAP as a heavily patented product. The relevant patent count is less important than whether any enforceable claims block an approved generic capsule.

For commercial analysis, the estate appears weak relative to protected specialty pharmaceuticals:

1. The active ingredient is old.
2. Doxycycline capsule technology is widely available.
3. Generic manufacturers have extensive market experience with the product.
4. A narrow method-of-use claim would not necessarily block all generic sales.
5. A manufacturing claim would usually be avoidable through an alternative process.

The absence of a strong patent estate does not eliminate litigation risk. It reduces the probability that litigation will produce a long period of delayed generic entry.

Which companies are challenging Acticlate CAP?

Doxycycline hyclate is supplied by multiple generic manufacturers, including large U.S. generic companies and contract manufacturers. Competition may arise through products referencing the same active ingredient and dosage form rather than through a direct branded challenge to Acticlate.

Potential competitive groups include:

• Large generic manufacturers with FDA-approved doxycycline capsules.
• Specialty generic companies focused on dermatology.
• Contract manufacturers supplying private-label products.
• Wholesaler and pharmacy purchasing organizations.
• Other branded doxycycline suppliers competing for dermatology prescriptions.

A Paragraph IV challenge is most relevant when an Orange Book-listed patent remains active. No major, publicly documented Paragraph IV campaign specifically targeting Acticlate CAP is a defining feature of the product’s current commercial position. The more important competitive event is continuing generic substitution.

What patent litigation affects Acticlate CAP?

Acticlate CAP does not have a widely recognized patent-litigation profile comparable to high-value products such as branded oncology agents, biologics or extended-release specialty medicines.

The likely litigation exposure is limited to:

• Patent disputes over a listed secondary patent.
• ANDA litigation involving a generic capsule applicant.
• Trademark or trade-dress disputes.
• Contract disputes involving distribution or co-promotion.
• Pricing or market-access disputes involving reimbursement intermediaries.

Because the active ingredient is off-patent and the dosage form is conventional, an ANDA dispute would be more likely to involve narrow formulation or labeling claims than the doxycycline molecule itself.

What generic entry risks exist for Acticlate CAP?

Generic entry risk is high and persistent. Doxycycline is a mature molecule with broad clinical acceptance, established manufacturing know-how and multiple approved alternatives.

The main generic-entry mechanisms are:

• Direct substitution at the pharmacy.
• Formulary preference for lower-cost products.
• Therapeutic use of generic doxycycline in place of branded products.
• Hospital and health-system purchasing contracts.
• Mail-order and specialty-pharmacy substitution.
• Increased prescriber use of generic prescriptions.

The capsule format does not create a strong switching barrier. Patients may experience differences in tolerability or excipients among manufacturers, but those differences generally do not support durable brand retention across the market.

How does Acticlate CAP compare with generic doxycycline?

Factor	Acticlate CAP	Generic doxycycline hyclate
Molecular ingredient	Doxycycline hyclate	Doxycycline hyclate
Brand recognition	Higher in selected dermatology channels	Low at patient level, high at pharmacy level
Price	Usually higher than generic alternatives	Lower
Patent protection	Limited	Not dependent on brand patents
Prescriber rationale	Brand familiarity, availability or commercial support	Cost, formulary preference and substitution
Reimbursement position	Vulnerable to unfavorable tiers	Usually preferred
Market access	Dependent on contracting	Supported by substitution rules
Long-term growth potential	Limited without differentiation	Stable demand but price pressured

Acticlate may retain use where prescribers prefer a branded product, where the company maintains targeted dermatology promotion, or where payer contracts reduce the apparent price difference. These advantages are commercial rather than technological.

What is the financial trajectory for Acticlate CAP?

No public filing provides a reliable standalone revenue series for Acticlate CAP. Avion’s private-company structure limits product-level financial disclosure. The financial trajectory must therefore be inferred from market structure, product maturity and pricing dynamics rather than reported brand revenue.

The likely trajectory has four phases:

Launch and brand-building phase

Acticlate could obtain initial traction through dermatologist promotion, product availability and positioning against other doxycycline products. The commercial objective would be to build prescription recognition and secure distribution.

Expansion phase

Revenue could increase if the product gained formulary access, captured branded prescriptions or benefited from limited competition in a particular strength or dosage form. Specialty dermatology promotion can support higher gross-to-net pricing than an unbranded generic.

Generic-pressure phase

As generic supply expands, pharmacies and payers apply substitution and formulary pressure. Gross sales may remain stable while net revenue declines because of rebates, discounts, co-pay support and wholesaler concessions.

Mature portfolio phase

The product becomes a cash-flow asset rather than a growth asset. Its value depends on manufacturing cost, inventory efficiency, contracting, channel retention and the ability to maintain a price premium.

Financial driver	Directional impact
Generic competition	Negative
Brand recognition among dermatologists	Positive
Payer preference	Negative unless contracted
Manufacturing scale	Positive
Wholesale discounts	Negative to net revenue
Dermatology promotion	Positive but costly
Supply reliability	Positive
Patent expiry	Limited incremental effect because core protection is already absent
Price increases	Potentially positive for gross sales, negative for volume and payer access

What revenue exposure does Acticlate CAP create?

Acticlate CAP is unlikely to represent a major strategic revenue platform unless it is part of a larger dermatology portfolio. A mature oral antibiotic faces structural limits:

• Treatment duration is usually finite.
• Chronic dermatology use may be restricted by safety and stewardship concerns.
• Generic alternatives cap sustainable pricing.
• Payers can impose substitution or prior authorization.
• Physicians have multiple doxycycline brands and generic options.
• Antibiotic resistance concerns constrain promotional positioning.

The product can still generate recurring revenue because acne, rosacea and bacterial infections create ongoing demand. Revenue quality is weaker than for chronic specialty drugs with strong reimbursement protection because prescriptions can migrate rapidly to lower-priced alternatives.

What manufacturing and intellectual-property barriers affect Acticlate CAP?

Manufacturing barriers are moderate to low. Doxycycline hyclate requires control of active-ingredient quality, dosage uniformity, dissolution, stability and contamination. These requirements matter for FDA compliance but do not normally prevent capable generic manufacturers from entering.

The strongest operational risks are:

• Active pharmaceutical ingredient supply disruption.
• Quality failures involving dissolution or assay.
• Capsule-shell or excipient shortages.
• FDA manufacturing observations.
• Product recalls.
• Inventory imbalances caused by low-margin generic competition.

A reliable supply chain can create temporary commercial value. It does not create durable exclusivity.

What generic launch scenarios are most likely?

The most likely scenario is continued coexistence between Acticlate CAP and multiple generic doxycycline capsules, with gradual erosion of branded volume and net price.

Scenario	Probability	Commercial outcome
Continued generic substitution	High	Lower volume and pricing pressure
Brand retention in selected dermatology practices	Medium	Stable niche revenue
Supply disruption among generics	Low to medium	Temporary volume and price benefit
Successful secondary-patent enforcement	Low	Limited delay to specific competitors
Major new indication	Low	Potential upside, but requires clinical and regulatory investment
Product withdrawal	Possible over the long term	Loss of revenue if economics deteriorate

How does Acticlate CAP compare with competing doxycycline brands?

Acticlate competes with generic doxycycline hyclate and other branded doxycycline products, including formulations positioned around gastrointestinal tolerability, delayed release or acne-specific use. Products with differentiated delivery systems can command stronger pricing than a conventional capsule.

Acticlate CAP’s relative weakness is the lack of an obvious technology-based advantage. Its relative strength is the established use of doxycycline and the ability to fit into a broader dermatology sales strategy.

Key Takeaways

• Acticlate CAP is a branded doxycycline hyclate capsule associated with Avion Pharmaceuticals.
• Doxycycline’s core molecule and conventional capsule technology are long off patent.
• The product has limited practical exclusivity and high exposure to generic substitution.
• No major public patent-litigation campaign defines its market position.
• Product-level revenue is not publicly disclosed, so the financial trajectory is inferred from market structure.
• The likely long-term profile is mature, price-sensitive revenue rather than high-growth branded sales.
• Commercial value depends on dermatology prescriber loyalty, payer access, manufacturing reliability and portfolio economics.
• A conventional capsule has weaker defensibility than a differentiated delayed-release or specialty delivery product.

FAQs About Acticlate CAP

Is Acticlate CAP the same as generic doxycycline?

Acticlate CAP contains doxycycline hyclate, the same active ingredient used in many generic doxycycline products. Substitution depends on the dosage form, strength, FDA therapeutic-equivalence rating and prescription requirements.

Does Acticlate CAP have a valid composition patent?

No meaningful remaining composition-of-matter protection is associated with doxycycline as an active ingredient. Any relevant protection would more likely involve a narrow formulation, method-of-use or manufacturing claim.

Can a pharmacy substitute generic doxycycline for Acticlate CAP?

A pharmacy may substitute an FDA-rated therapeutically equivalent product where state law, the prescription and payer rules permit substitution. The exact result depends on the prescribed strength and dosage form.

Is Acticlate CAP a high-growth pharmaceutical asset?

No. It is better characterized as a mature branded product with niche retention potential. Growth would require differentiated clinical positioning, improved reimbursement or expansion within a broader dermatology portfolio.

What would increase the value of Acticlate CAP?

Value could improve through reliable supply, favorable payer contracting, stronger dermatologist adoption, reduced manufacturing cost or a differentiated clinical and formulation claim. None of these factors would replicate the economic protection of a new chemical entity patent.

References

1. U.S. Food and Drug Administration. (2024). Doxycycline hyclate prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
4. Avion Pharmaceuticals. (2024). Acticlate product information. Avion Pharmaceuticals.